JULIANA FERRAZ ROSA

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
Projetos de Pesquisa
Unidades Organizacionais
LIM/54 - Laboratório de Bacteriologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Assunto: genes ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 5 Citação(ões) na Scopus
    Smqnr VARIANTS IN CLINICAL ISOLATES OF Stenotrophomonas maltophilia IN BRAZIL
    (2013) GRACIA-PAEZ, Jorge Isaac; FERRAZ, Juliana Rosa; SILVA, Ivan Avelino Franca E; ROSSI, Flavia; LEVIN, Anna Sara; COSTA, Silvia Figueiredo
    Stenotrophomonas maltophilia contains a novel chromosomally-encoded qnr gene named Smqnr that contributes to low intrinsic resistance to quinolone. We described Smqnr in 13 clinical isolates of S. maltophilia from two Brazilian hospitals, over a 2-year period. The strains were identified by API 20 NE (bioMerieux, France). Susceptibility by microdilution method to trimetroprim/sulfamethoxazole, ciprofloxacin, levofloxacin, minocycline, ceftazidime, chloramphenicol and ticarcillin/clavulanate was performed according to CLSI. PCR detection of Smqnr gene was carried out. The sequence of Smqnr was compared with those deposited in GenBank. Pulsed-field gel electrophoresis (PFGE) of all strains was performed. Thirteen Smqnr positives isolates were sequenced and three novel variants of Smqnr were identified. All 13 Smqnr isolates had distinguishable patterns by PFGE. This is the first report of Smqnr in S. maltophilia isolated in Brazil.
  • article 33 Citação(ões) na Scopus
    In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives
    (2015) RIZEK, Camila; FERRAZ, Juliana Rosa; HEIJDEN, Inneke Marie van der; GIUDICE, Mauro; MOSTACHIO, Anna Karina; PAEZ, Jorge; CARRILHO, Claudia; LEVIN, Anna Sara; COSTA, Silvia F.
    Background: The aim of this study was to evaluate the in vitro susceptibility of MDR gram-negatives bacteria to old drugs such as polymyxin B, minocycline and fosfomycin and new drugs such as tigecycline. Methods: One hundred and fifty-three isolates from 4 Brazilian hospitals were evaluated. Forty-seven Acinetobacter baumannii resistant to carbapenens harboring adeB, bla(OxA23), bla(OxA51), bla(OxA143) 23, and bla(IMP) genes, 48 Stenotrophomonas maltophilia including isolates resistant to levofloxacin and/or trimethoprim-sulfamethoxazole harboring sul-1, sul-2 and qnr(MR) and 8 Serratia marcescens and 50 Klebsiella pneumoniae resistant to carbapenens harboring bla(KPC-2) were tested to determine their minimum inhibitory concentrations (MICs) by microdilution to the following drugs: minocycline, ampicillin-sulbactam, tigecycline, and polymyxin B and by agar dilution to fosfomycin according with breakpoint criteria of CLSI and EUCAST (fosfomycin). In addition, EUCAST fosfomycin breakpoint for Pseudomonas spp. was applied for Acinetobacter spp and S. maltophilia, the FDA criteria for tigecycline was used for Acinetobacter spp and S. maltophilia and the Pseudomonas spp polymyxin B CLSI criterion was used for S. maltophilia. Results: Tigecycline showed the best in vitro activity against the MDR gram-negative evaluated, followed by polymyxin B and fosfomycin. Polymyxin B resistance among K. pneumoniae was detected in 6 isolates, using the breakpoint of MIC > 8 ug/mL. Two of these isolates were resistant to tigecycline. Minocycline was tested only against S. maltophilia and A. baumannii and showed excellent activity against both. Conclusions: Fosfomycin seems to not be an option to treat infections due to the A. baumannii and S. maltophilia isolates according with EUCAST breakpoint, on the other hand, showed excellent activity against S. marcescens and K. pneumoniae. (C) 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.